New products to lead Nicholas topline growth - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

New products to lead Nicholas topline growth

Apr 25, 2000

Nicholas Piramal has reported an above average topline growth of 13% (vis–a–vis the overall domestic pharmaceutical growth of 9%) primarily due to introduction of new products which contributed around Rs 500 m to the topline. These products were in the relatively faster growing cardiovascular segment. The other positives for the company during the year were the sale of its bulk drug business, the price revision allowed for Vitamin A (which would yield Rs 40 m next year) and the restructuring of its facility at Deonar which yielded cost benefits.

(Rs m) FY1999 FY2000 Change
Sales 4300.00 4865.00 13.1%
Other Income 188.00 182.00 -3.2%
Expenditure 3746.00 4200.00 12.1%
Operating Profit (EBDIT) 554.00 665.00 20.0%
Operating Profit Margin (%) 12.88% 13.67%  
Interest (net) 145.00 112.00 -22.8%
Depreciation 89.00 106.00 19.1%
Profit before Tax 508.00 629.00 23.8%
Other Adjustments      
Tax 55.00 60.00 9.1%
Profit after Tax/(Loss) 453.00 569.00 25.6%
Net profit margin (%) 10.53% 11.70%  

Equitymaster requests your view! Post a comment on "New products to lead Nicholas topline growth". Click here!


More Views on News

PIRAMAL ENTERPRISES 2020-21 Annual Report Analysis (Annual Result Update)

Oct 26, 2021 | Updated on Oct 26, 2021

Here's an analysis of the annual report of PIRAMAL ENTERPRISES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of PIRAMAL ENTERPRISES. Also includes updates on the valuation of PIRAMAL ENTERPRISES.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY22); Net Profit Down 20.0% (Quarterly Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

For the quarter ended June 2021, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (down 20.0% YoY). Sales on the other hand came in at Rs 29 bn (down 1.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 7, 2021 03:07 PM


  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks